You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 13, 2025

CLINICAL TRIALS PROFILE FOR ANAFRANIL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Anafranil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00018200 ↗ Effect of Antidepressants on Back Pain Completed US Department of Veterans Affairs Phase 2 1999-04-01 The purpose of this study is to determine whether different types of antidepressant medicines relieve back pain that has lasted at least six months on a daily basis. Study participants will be assigned to treatment with either a antidepressant acting on the serotonin system in the brain (fluoxetine), one acting on the noradrenaline system (desipramine, or to a control medication not expected to relieve pain (benztropine). Each participant will be seen at least nine times during their 12 weeks on medication. This is a phase 2/3, outpatient study.
NCT00018200 ↗ Effect of Antidepressants on Back Pain Completed VA Office of Research and Development Phase 2 1999-04-01 The purpose of this study is to determine whether different types of antidepressant medicines relieve back pain that has lasted at least six months on a daily basis. Study participants will be assigned to treatment with either a antidepressant acting on the serotonin system in the brain (fluoxetine), one acting on the noradrenaline system (desipramine, or to a control medication not expected to relieve pain (benztropine). Each participant will be seen at least nine times during their 12 weeks on medication. This is a phase 2/3, outpatient study.
NCT00466609 ↗ Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed Conselho Nacional de Desenvolvimento Científico e Tecnológico Phase 4 2007-05-01 This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Anafranil

Condition Name

Condition Name for Anafranil
Intervention Trials
Obsessive Compulsive Disorder 3
Back Pain 2
Depression 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Anafranil
Intervention Trials
Compulsive Personality Disorder 3
Compulsive Behavior 3
Depression 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Anafranil

Trials by Country

Trials by Country for Anafranil
Location Trials
Brazil 2
United States 2
Canada 1
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Anafranil
Location Trials
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Anafranil

Clinical Trial Phase

Clinical Trial Phase for Anafranil
Clinical Trial Phase Trials
Phase 4 2
Phase 2 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Anafranil
Clinical Trial Phase Trials
Completed 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Anafranil

Sponsor Name

Sponsor Name for Anafranil
Sponsor Trials
University of Sao Paulo 2
Sandoz 2
VA Office of Research and Development 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Anafranil
Sponsor Trials
Other 13
Industry 3
U.S. Fed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Anafranil: Clinical Trials, Market Analysis, and Projections

Introduction to Anafranil

Anafranil, known generically as clomipramine, is a tricyclic antidepressant commonly used to treat various mental health conditions, including obsessive-compulsive disorder (OCD), panic disorder, and depression. Here, we will delve into the current state of clinical trials, market analysis, and future projections for this medication.

Clinical Trials Update

Active Clinical Trials

As of the latest data, there are numerous active clinical trials assessing the efficacy and safety of Anafranil for various indications.

  • Obsessive-Compulsive Disorder (OCD): There are 18 active clinical trials, with phases ranging from Early Phase 1 to Phase 3. These trials aim to evaluate the effectiveness of clomipramine in managing OCD symptoms and improving patient outcomes[1].
  • Panic Disorder: Fifteen clinical trials are actively recruiting participants to study the use of clomipramine in treating panic disorder. These trials span across different phases, including Phase 2[1].
  • Depression: A significant number of clinical trials, 333 in total, are focused on evaluating clomipramine's potential in treating depression. These trials cover a wide range of phases, from Phase 1 to Phase 4[1].

Novel Uses and Emerging Trends

In addition to its traditional uses, clomipramine is being explored for other conditions. For instance, there is ongoing research into its potential for treating cataplexy associated with narcolepsy and nocturnal enuresis. These novel uses could expand the market for Anafranil and provide new treatment options for patients[2].

Market Analysis

Market Size and Growth

The global clomipramine market is anticipated to experience significant growth over the forecast period of 2022-2029. According to market research, the clomipramine market is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.40% during this period[3].

Market Drivers

Several factors are driving the growth of the clomipramine market:

  • Increasing Prevalence of OCD and Depression: The rising prevalence of obsessive-compulsive disorder and depression globally is a major driver for the expansion of the clomipramine market[3].
  • Advancements in Formulation: Innovations in clomipramine formulation, such as improved patient compliance and reduced side effects, are enhancing its market appeal[2].
  • Digital Pharmacy Platforms: The increased availability of clomipramine through digital pharmacy platforms is expanding consumer access and contributing to market growth[2].

Market Restraints

Despite the positive trends, there are several challenges affecting the market:

  • Side Effects: Clomipramine is associated with various side effects, including diarrhea, headache, nausea, vomiting, drowsiness, and others, which can hamper market growth[3].
  • Regulatory Challenges: Regulatory hurdles and the lack of significant marketing initiatives can impact the market presence of clomipramine[2].
  • Generic Competition: The presence of generic competitors affects the pricing strategy and overall market dynamics of clomipramine[2].

Market Opportunities

There are several opportunities for growth and expansion in the clomipramine market:

  • Emerging Markets: Strategic penetration into emerging markets with burgeoning healthcare systems and increasing adoption of mental health treatments offers significant growth potential[2].
  • Pediatric Applications: Research into the use of clomipramine as an anxiety treatment in pediatric populations presents a new market opportunity[2].
  • Collaboration with Advocacy Groups: Collaborations with mental health advocacy groups for awareness campaigns can strengthen market position and uptake[2].

Market Segmentation

By Application

Clomipramine is used to treat a variety of conditions, including:

  • Obsessive-Compulsive Disorder: This remains one of the primary applications of clomipramine.
  • Depression: Clomipramine is also widely used in the treatment of depression.
  • Panic Attack: It is used to manage symptoms of panic disorder.
  • Other Conditions: It is also used in treating schizophrenia, Tourette syndrome, and other compulsive disorders[3].

By Demographic

The market is segmented by demographic groups, including:

  • Adult: The largest demographic segment for clomipramine.
  • Pediatric: Emerging as a potential growth area.
  • Geriatric: Increasing geriatric population is another factor driving market growth[3].

By Distribution Channel

The distribution channels for clomipramine include:

  • Hospital Pharmacy: A significant distribution channel.
  • Retail Pharmacy: Another major channel.
  • Online Pharmacy: Increasingly important due to expanded consumer access[3].

Competitive Landscape

The clomipramine market is competitive, with several key players:

  • Aurobindo Pharma Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Jagsonpal Pharmaceuticals Ltd.
  • Lannett Company, Inc.
  • Mallinckrodt Pharmaceuticals
  • Mylan N.V. (now part of Viatris Inc.)
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zee Laboratories Ltd.[2].

These companies are focusing on product innovation, strategic investments, and market penetration to maintain their competitive edge.

Product Development and Innovation

The market is driven by ongoing research and development activities, including:

  • Formulation Advancements: Efforts to minimize adverse effects and improve patient compliance through advanced formulations.
  • Personalized Medicine: Approaches tailored to individual patient profiles.
  • Clomipramine Analogs: Development of analogs with improved efficacy and reduced side effects[2].

Key Takeaways

  • Clinical Trials: Numerous active clinical trials are evaluating the efficacy of Anafranil for OCD, panic disorder, and depression.
  • Market Growth: The global clomipramine market is expected to grow at a CAGR of 4.40% from 2022 to 2029.
  • Market Drivers: Increasing prevalence of OCD and depression, advancements in formulation, and expanded consumer access through digital platforms.
  • Market Restraints: Side effects, regulatory challenges, and generic competition.
  • Market Opportunities: Emerging markets, pediatric applications, and collaborations with advocacy groups.
  • Competitive Landscape: Several key players are driving innovation and market penetration.

FAQs

What is Anafranil used for?

Anafranil, or clomipramine, is used to treat obsessive-compulsive disorder (OCD), panic disorder, depression, and other compulsive disorders.

What are the common side effects of Anafranil?

Common side effects include diarrhea, headache, nausea, vomiting, drowsiness, dry mouth, constipation, nervousness, and seizures.

How is the clomipramine market expected to grow?

The global clomipramine market is expected to grow at a CAGR of 4.40% from 2022 to 2029.

What are the key drivers of the clomipramine market?

Key drivers include the increasing prevalence of OCD and depression, advancements in formulation, and expanded consumer access through digital platforms.

Which companies are major players in the clomipramine market?

Major players include Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Jagsonpal Pharmaceuticals Ltd., Lannett Company, Inc., and others.

Sources

  1. Withpower.com: Anafranil: Everything you need to know | Power - Clinical Trials
  2. 360iResearch: Clomipramine Market Size & Share 2025-2030
  3. Data Bridge Market Research: Global Clomipramine Market - Industry Trends and Forecast to 2029
  4. JAMA Network: Intravenous Clomipramine for Obsessive-Compulsive Disorder[1][2][3]
Last updated: 2025-01-02

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.